



# ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006  
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad  
E-mail : [ishitadrugs@gmail.com](mailto:ishitadrugs@gmail.com) | [info@ishitadrugs.com](mailto:info@ishitadrugs.com) | URL : [www.ishitadrugs.com](http://www.ishitadrugs.com)  
Phone : +91 7226995613/14/15 | +91 79 4002 3839

Date: 13.08.2024

To,  
The Department of Corporate Services,  
BSE Limited.  
Floor No. 25, Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001.

**Scrip Code: 524400**

Dear Sir/Madam,

**Subject: Outcome of Board Meeting held on 13<sup>th</sup> August, 2024**

Pursuant to the regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 13<sup>th</sup> August, 2024 have

1. Approved the Unaudited Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2024. The Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith.
2. Based on the recommendation of Nomination and Remuneration Committee, Board of Directors approved the appointment of Ms. Dhvani Solanki (DIN- 10299290) as an Additional Director in the category of Non- executive Independent Director of the Company, for an initial term of 5 years, which is subject to the approval of the shareholders of the Company.

The required details pursuant to SEBI Listing regulations are annexed herewith as **Annexure - I.**

3. Acceptance of the Resignation received from Mr. Niranjana Agarwal [ DIN: 06503361], non-executive independent Director of the Company, due to his personal reasons, with effect from close of business hours on 13<sup>th</sup> August, 2024.

There are no other material reasons for his resignation other than those mentioned in his resignation letter.

*"Our basic drugs in the service of humanity worldwide"*

CIN No. L24231GJ1992PLC017054  
D & B D-U-N-S Number - 65-018-0359



# ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : [ishitadrugs@gmail.com](mailto:ishitadrugs@gmail.com) | [info@ishitadrugs.com](mailto:info@ishitadrugs.com) | URL : [www.ishitadrugs.com](http://www.ishitadrugs.com)

Phone : +91 7226995613/14/15 | +91 79 4002 3839

---

The details required in terms of regulation 30 read with Schedule III- Para A(7B) of Part A of the Listing regulations and SEBI Circulars issued in this regard, are given in **Annexure – II**. The letter of resignation received from Mr. Niranjana Agarwal is enclosed herewith in **Annexure – III**.

4. Considered and approved the amendment in the Notice for convening the 31<sup>st</sup> Annual General Meeting of the Company.

The composition of Board of Directors of the Company is in compliance with the requirements prescribed under the Companies Act, 2013 and SEBI Listing Regulations.

The meeting was commenced at 06:30 p.m. and concluded at 07: 00 p.m.

Please take the above details on your records.

Thanking You.

**For, Ishita Drugs and Industries Limited**

**Jagdish Agrawal**  
**Managing Director**

*"Our basic drugs in the service of humanity worldwide"*

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359

Date: 13/08/2024

To,  
The Board of Directors,  
Ishita Drugs & Industries Limited,  
Ahmedabad.

**LIMITED REVIEW REPORT**

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 Apr 2024 to 30 Jun 2024**. (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of  
**JAYMIN SHAH & ASSOCIATES**

Chartered Accountants

CA Mayank Sancheti

M No. :170863

Date: 13/08/2024

Place: Ahmedabad

UDIN: 24170863BKAROO8452





**ISHITA DRUGS AND INDUSTRIES LIMITED**

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

**Unaudited Financial Results for the Quarter Ended June 30, 2024**

Amount in Lacs except Per Share data

Particulars		Figures for 3 Months Ended	Figures for Preceding 3 Months Ended	Figures for Corresponding 3 Months in the previous Year Ended	Figures for the previous year Ended
		Un-audited	Audited	Un-audited	Audited
		30-Jun-24	31-Mar-24	30-Jun-23	31-Mar-24
1	<b>INCOME</b>				
	Revenue from Operations	302.76	449.61	308.63	1518.76
	Other Income	5.83	10.39	7.43	28.02
	<b>Total Income</b>	<b>308.59</b>	<b>459.99</b>	<b>316.06</b>	<b>1546.79</b>
2	<b>EXPENSES</b>				
(a)	Cost of Material Consumed	185.21	362.80	223.67	1137.46
(b)	Purchase of Stock-In-Trade	4.30	0.00	0.00	6.40
(c)	Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	18.07	(11.23)	(12.05)	(14.51)
(d)	Employee Benefit Expense	34.39	34.10	31.10	133.89
(e)	Finance Cost	0.78	1.57	2.61	8.98
(f)	Depreciation, Depletion and Amortisation Expense	2.79	1.17	3.43	11.17
(g)	Other Expense	43.41	34.60	49.07	164.67
	<b>Total Other Expenses</b>	<b>43.41</b>	<b>34.60</b>	<b>49.07</b>	<b>164.67</b>
	<b>Total Expenses</b>	<b>288.96</b>	<b>423.01</b>	<b>297.82</b>	<b>1448.06</b>
3	<b>Total Profit before Exceptional Items and Tax</b>	<b>19.64</b>	<b>36.99</b>	<b>18.23</b>	<b>98.73</b>
4	Exceptional Items	0.00	0.00	0.00	0.00
5	<b>Total Profit before Tax</b>	<b>19.64</b>	<b>36.99</b>	<b>18.23</b>	<b>98.73</b>
6	Tax Expense				
7	Current Tax	4.90	8.93	4.50	24.00
8	Deferred Tax	0.00	(0.12)	0.00	(0.12)
9	<b>Total Tax Expenses</b>	<b>4.90</b>	<b>8.80</b>	<b>4.50</b>	<b>23.88</b>
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00		0.00	0.00
11	<b>Net Profit Loss for the period from continuing operations</b>	<b>14.74</b>	<b>28.19</b>	<b>13.73</b>	<b>74.85</b>

*Jaydevi Agrawal*



12	Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00
13	Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00
14	Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00
15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00
16	<b>Total Profit / (Loss) for the period</b>	<b>14.74</b>	<b>28.19</b>	<b>13.73</b>	<b>74.85</b>
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00
18	<b>Total Comprehensive Income for the Period</b>	<b>14.74</b>	<b>28.19</b>	<b>13.73</b>	<b>74.85</b>
19	<b>Total profit or loss attributable to</b>				
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00
20	<b>Total comprehensive income for the period attributable to</b>				
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00
21	<b>Details of Equity Share Capital</b>				
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00
22	<b>Details of Debt Securities</b>				
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00
25	<b>Earnings Per Share</b>				
(i)	<b>Earnings Per Share for continuing operations</b>				
	Basic Earnings / (Loss) per share from continuing operations	0.49	0.94	0.46	2.50
	Diluted Earnings / (Loss) per share from continuing operations	0.49	0.94	0.46	2.50
(ii)	<b>Earnings Per Share for discontinued operations</b>				
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00
(iii)	<b>Earnings per Equity Share</b>				
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.49	0.94	0.46	2.50
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.49	0.94	0.46	2.50
26	Debt Equity Ratio	0.00	0.00	0.00	0.00
27	Debt Service Coverage Ratio	0.00	0.00	0.00	0.00
28	Interest Service Coverage Ratio	0.00	0.00	0.00	0.00



**NOTES**

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 13, 2024.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter ended 30th June, 2024 are Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website [www.ishitadrugs.com](http://www.ishitadrugs.com) and also at [www.bseindia.com](http://www.bseindia.com).

For, **ISHITA DRUGS AND INDUSTRIES LIMITED****JAGDISH AGRAWAL**Place **Ahmedabad****MANAGING DIRECTOR**Date **13-Aug-24****DIN: 01031687**



# ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : [ishitadrugs@gmail.com](mailto:ishitadrugs@gmail.com) | [info@ishitadrugs.com](mailto:info@ishitadrugs.com) | URL : [www.ishitadrugs.com](http://www.ishitadrugs.com)

Phone : +91 7226995613/14/15 | +91 79 4002 3839

## Annexure - I

### Information as required under Regulation 30 - of SEBI

#### (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr.No.	Particulars	Details
1.	Reasons for Change viz. appointment, <del>resignation</del> , removal, otherwise;	Appointment of Ms. Dhvani Solanki [DIN: 10299290] as an Additional Director in the category of Non-executive Independent Director. (Based on the recommendation of Nomination and Remuneration committee)
2.	Date of appointment / <del>cessation</del> (as applicable) & terms of appointment	Date of appointment shall be the date of approval of the shareholders.  Terms of Appointment: for a term of 5 years commencing from the date of appointment.
3.	Brief Profile	Ms. Dhvani Solanki is a Qualified Company Secretary with more than 10 years of experience working in private and public listed companies.  She is involved in various statutory compliances and day to day accounting activities like GST registration and also in secretarial and Internal Audit, matters related to RBI and foreign exchange trading laws and regulations.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Ms. Dhvani Solanki is not related to any of the Directors of the Company.
5.	Declaration as required under Circular No. LIST/COMP/14/2018-19 dated June 20, 2018	Ms. Dhvani Solanki is not debarred from holding office of a director by virtue of any SEBI order or any other such authority.

*"Our basic drugs in the service of humanity worldwide"*

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359



# ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad

E-mail : [ishitadrugs@gmail.com](mailto:ishitadrugs@gmail.com) | [info@ishitadrugs.com](mailto:info@ishitadrugs.com) | URL : [www.ishitadrugs.com](http://www.ishitadrugs.com)

Phone : +91 7226995613/14/15 | +91 79 4002 3839

## Annexure - II

### Information as required under Regulation 30 - of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	Details
1.	Reasons for Change viz. appointment, resignation, removal, otherwise;	Resignation of Mr. Niranjan Agarwal, Non-executive Independent Director of the Company with effect from the close of business hours on 13 <sup>th</sup> August, 2024.
2.	Date of Appointment/Cessation (as applicable) & Term of appointment	Cessation with effect from close of business hours on 13 <sup>th</sup> August, 2024.
3.	Brief Profile (in case of Appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
5.	Other Directorships / Memberships (in listed entities in case of resignation of independent director)	BAMNI BAZAR TEXTILE PRIVATE LIMITED
6.	Letter of resignation along with detailed reason for resignation	Enclosed herewith in Annexure III
7.	The Independent director shall, along with the detailed reasons, also provide a confirmation that there are no other material reasons other than those provided.	Mr. Niranjan Agarwal has confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter.

*"Our basic drugs in the service of humanity worldwide"*

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359



Date: 13.08.2024

The Board of Directors of  
Ishita Drugs and Industries Limited  
Survey No 179/1,  
Vasna-Iyava, Taluka Sanand,  
Ahmedabad, Gujarat, India, 382210

Dear Sir/Madam,

**Subject: Resignation as an Independent Director of the Company**

Due to certain unavoidable personal situations, I hereby tender my resignation from the post of Non-executive Independent Director of the company with effective from close of business hours on 13<sup>th</sup> August, 2024.


I confirm that there is no material reason for my resignation other than stated therein.

I am thankful for the opportunity given to me to serve on the Board, and would like to thank all the Board members and the Management team for the support extended to me during my tenure.

Kindly acknowledgement the receipt of this resignation letter and do the needful in the procedural matters related to this.

Thanking You.

Yours Faithfully,



**NIRANJANA AGARWAL**

**Director**

**DIN: 06503361**